Actively Recruiting
Neural Correlates of Stress and Perceived Control in Adolescent Depression
Led by Mclean Hospital · Updated on 2025-05-07
80
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lack of perceived control, particularly during stress, has been critically implicated in major depressive disorder (MDD) and anhedonic symptoms, especially among female adolescents; yet the neural underpinnings of perceived control disruptions in MDD remain poorly understood. Using functional magnetic resonance imaging with a novel "value of control task" in conjunction with a prospective design, this study will provide a comprehensive understanding of stress and perceived control related mechanisms in female adolescents with MDD and will examine stress-induced disruptions in perceived control as a predictor of "real world" expressions of maladaptive coping and anhedonia.
CONDITIONS
Official Title
Neural Correlates of Stress and Perceived Control in Adolescent Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female adolescents aged 14 to 18 years
- Written informed assent/consent from adolescent and parent/guardian if under 18
- English as a first language or fluent in English
- Right-handed
- Personal cell phone available for surveys
- In the follicular phase of menstrual cycle during fMRI session
- For MDD group: meet DSM-5 criteria for major depressive disorder diagnosed by KSADS
- No psychotropic medications for at least 2 weeks (6 weeks for fluoxetine, 6 months for neuroleptics, 2 weeks for benzodiazepines or other antidepressants)
- For healthy controls: no current or past DSM-5 psychiatric or substance/alcohol disorders
- No first-degree relatives with history of depression, bipolar disorder, or psychosis
You will not qualify if you...
- History of head trauma with loss of consciousness
- History of seizure disorder
- Serious or unstable medical illnesses (cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, hematologic)
- History of cocaine or stimulant use (including amphetamine, cocaine, methamphetamine)
- History of dopaminergic drug use (including methylphenidate)
- Use of hormonal replacement therapy, anabolic steroids, or hormonal contraception
- Clinical or lab evidence of hypothyroidism
- Systemic medical or neurological illness affecting fMRI cerebral blood flow
- Standard fMRI exclusions (claustrophobia, pacemakers, metal implants, cochlear implants, metal braces)
- Pregnancy
- Positive drug test on scan day for stimulants, marijuana, barbiturates, benzodiazepines, buprenorphine, MDMA, methadone, opiates, oxycodone, phencyclidine
- History of electroconvulsive therapy
- Suicidal ideation deemed unsafe for participation
- For MDD group: MDD diagnosis secondary to another disorder (selected anxiety disorders allowed if secondary to MDD)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
McLean Hospital
Belmont, Massachusetts, United States, 02478
Actively Recruiting
Research Team
E
Emily L Belleau, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here